Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Cysteine Hydrochloride

FDA-approved product (injectable, injection), marketed as Cysteine Hydrochloride, Elcys, Nouress.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
0 of 4

Chemical structure

Chemical structure of Cysteine Hydrochloride
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Liver disease

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

Anti-infective classification
Neither a WHO ATC code nor an FDA pharmacologic class was found for it, so whether it is already an antimicrobial is not established. It needs review and is not counted as a repurposing candidate.

Repurposing investigation

No supported pathogen reaches ≥40% AI-predicted activity for Cysteine Hydrochloride, so it is not among the repurposing candidates. Its predictions are shown below.

AI-predicted activity

AI prediction · nothing measured
  • MRSA9.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli8.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae8.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis17.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Cysteine Hydrochloride in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Cysteine Hydrochloride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Safety And Tolerability Of Gamma Glutamylcysteine (GGC) Oral Supplementation In MCI Patients

    NCT07583251 · start 2026-08-04

    Registered record
    Registry ID
    NCT07583251
    Conditions
    Mild Cognitive Impairment (MCI)
    Interventions
    Gamma- Glutamylcysteine; Gamma- Glutamylcysteine; Gamma- Glutamylcusteine
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Recruiting
    Start
    2026-08-04
    Completion
    2027-02
    Enrolment
    9

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMild Cognitive Impairment (MCI)
    InterventionGamma- Glutamylcysteine; Gamma- Glutamylcysteine; Gamma- Glutamylcusteine
    PhasePhase 1
    Registry statusRecruiting

  • Effect of N-acetylcysteine as Adjunct Therapy on the Clinical Outcome of Neonatal Sepsis

    NCT07380347 · start 2026-02

    Registered record
    Registry ID
    NCT07380347
    Conditions
    Neonatal Sepsis
    Interventions
    N-Acetyl Cysteine (NAC); Normal Saline
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Not yet recruiting
    Start
    2026-02
    Completion
    2026-08
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNeonatal Sepsis
    InterventionN-Acetyl Cysteine (NAC); Normal Saline
    PhasePhase 3
    Registry statusNot yet recruiting

  • The Effect of Three Different Medications on Anesthetic Success and Postoperative Pain

    NCT06298383 · start 2025-06-15

    Registered record
    Registry ID
    NCT06298383
    Conditions
    Symptomatic Irreversible Pulpitis
    Interventions
    Trypsin, Bromelain and Rutoside; Diclofenac Potassium 50mg Tab; Prednisolone Oral Tablet; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2025-06-15
    Completion
    2026-03-15
    Enrolment
    124

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSymptomatic Irreversible Pulpitis
    InterventionTrypsin, Bromelain and Rutoside; Diclofenac Potassium 50mg Tab; Prednisolone Oral Tablet; Placebo
    PhaseNot applicable
    Registry statusCompleted

  • Effect of Topical Bromelain Versus Topical Corticosteroids in the Management of Recurrent Aphthous Stomatitis

    NCT06993337 · start 2025-06-15

    Registered record
    Registry ID
    NCT06993337
    Conditions
    Recurrent Aphthous Stomatitis
    Interventions
    35% Topical Bromelain in Orabase; 50% Topical Bromelain in Orabase; 0.1% Topical Triamcinolone Acetonide in Orabase
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2025-06-15
    Completion
    2026-06-15
    Enrolment
    63

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRecurrent Aphthous Stomatitis
    Intervention35% Topical Bromelain in Orabase; 50% Topical Bromelain in Orabase; 0.1% Topical Triamcinolone Acetonide in Orabase
    PhasePhase 2
    Registry statusNot yet recruiting

  • N-Acetylcysteine as Therapy for Transplantation- Associated Thrombotic Microangiopathy

    NCT07279610 · start 2024-05-01

    Registered record
    Registry ID
    NCT07279610
    Conditions
    Thrombotic Microangiopathy
    Interventions
    N-Acetylcysteine (NAC) Treatment
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Active not recruiting
    Start
    2024-05-01
    Completion
    2026-12-31
    Enrolment
    44

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionThrombotic Microangiopathy
    InterventionN-Acetylcysteine (NAC) Treatment
    PhasePhase 2 / Phase 3
    Registry statusActive not recruiting

  • Effect of Sublingually Generated S-nitroso-N-acetylcysteine on Systemic Blood Pressure.

    NCT05798481 · start 2024-03-27

    Registered record
    Registry ID
    NCT05798481
    Conditions
    Hypertension; Cardiovascular Diseases
    Interventions
    Mixture of Sodium Nitrite and N-acetylcysteine (NAC) crytals.
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Completed
    Start
    2024-03-27
    Completion
    2025-10-05
    Enrolment
    14

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension; Cardiovascular Diseases
    InterventionMixture of Sodium Nitrite and N-acetylcysteine (NAC) crytals.
    PhaseEarly phase 1
    Registry statusCompleted

  • A Study to Explore if Long-term Use of Mucinex Can Help With Symptoms in Patients With Stable Chronic Bronchitis.

    NCT05843669 · start 2023-07-17

    Registered record
    Registry ID
    NCT05843669
    Conditions
    Chronic Bronchitis
    Interventions
    Guafenesin tablets
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2023-07-17
    Completion
    2024-11-13
    Enrolment
    82

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Bronchitis
    InterventionGuafenesin tablets
    PhasePhase 4
    Registry statusCompleted

  • A Study of NAC for AUD

    NCT04964843 · start 2023-04

    Registered record
    Registry ID
    NCT04964843
    Conditions
    Alcohol Use Disorder
    Interventions
    N-acetylcysteine; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Withdrawn
    Start
    2023-04
    Completion
    2025-01
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAlcohol Use Disorder
    InterventionN-acetylcysteine; Placebo
    PhasePhase 2
    Registry statusWithdrawn

  • Antiplatelet Therapies in Patients With Depression and Coronary Disease

    NCT05821062 · start 2022-04-14

    Registered record
    Registry ID
    NCT05821062
    Conditions
    Coronary Artery Disease; Depression
    Interventions
    standard Aspirin (ASA) + clopidogrel (CLP) therapy; standard Aspirin (ASA) + Ticagrelor (TCG) or Prasugrel (PSG) therapy; standard ASA therapy
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2022-04-14
    Completion
    2024-02
    Enrolment
    400

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCoronary Artery Disease; Depression
    Interventionstandard Aspirin (ASA) + clopidogrel (CLP) therapy; standard Aspirin (ASA) + Ticagrelor (TCG) or Prasugrel (PSG) therapy; standard ASA therapy
    PhaseNot recorded
    Registry statusUnknown

  • Effect of Acetaminophen and N-Acetylcysteine on Liver Metabolism on Homocystinuria

    NCT04015557 · start 2022-02-11

    Registered record
    Registry ID
    NCT04015557
    Conditions
    CBS Deficiency
    Interventions
    Acetaminophen; N-acetylcysteine
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Suspended
    Start
    2022-02-11
    Completion
    2022-12-01
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCBS Deficiency
    InterventionAcetaminophen; N-acetylcysteine
    PhasePhase 1 / Phase 2
    Registry statusSuspended

  • Intravenous NAC Use in ACLF Patients

    NCT05089981 · start 2021-11-01

    Registered record
    Registry ID
    NCT05089981
    Conditions
    Acute on Chronic Liver Failure(ACLF)
    Interventions
    N acetyl cysteine; Placebo of N acetyl cysteine
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2021-11-01
    Completion
    2023-03-01
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute on Chronic Liver Failure(ACLF)
    InterventionN acetyl cysteine; Placebo of N acetyl cysteine
    PhaseNot applicable
    Registry statusUnknown

  • Povidone-Iodine Nasal Irrigation After Surgery for Chronic Rhinosinusitis

    NCT07470242 · start 2021-10-13

    Registered record
    Registry ID
    NCT07470242
    Conditions
    Chronic Rhinosinusitis
    Interventions
    Normal Saline Nasal Irrigation; Acetylcysteine (Mucomyst) Nasal Irrigation; Povidone-Iodine Nasal Irrigation
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2021-10-13
    Completion
    2023-08-07
    Enrolment
    48

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Rhinosinusitis
    InterventionNormal Saline Nasal Irrigation; Acetylcysteine (Mucomyst) Nasal Irrigation; Povidone-Iodine Nasal Irrigation
    PhaseNot applicable
    Registry statusCompleted

  • Targeting the Neurobiology of RRB in Autism Using N-acetylcysteine: Single-dose

    NCT04278898 · start 2021-02-12

    Registered record
    Registry ID
    NCT04278898
    Conditions
    Autism Spectrum Disorder
    Interventions
    N-Acetylcysteine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2021-02-12
    Completion
    2029-01-31
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAutism Spectrum Disorder
    InterventionN-Acetylcysteine
    PhasePhase 2
    Registry statusRecruiting

  • Effects of Bromelain and Boswellia Serrata Casperome With Centella Asiatica and Vitamins on Edema, Paresthesia and Postoperative Pain After Quadrantectomy With or Without Sentinel Lymph Node Biopsy.

    NCT04669119 · start 2020-12-31

    Registered record
    Registry ID
    NCT04669119
    Conditions
    Breast Cancer Female; Pain, Postoperative
    Interventions
    Bromelain/Boswellia Serrata Casperome; Centella Asiatica/Vitamins; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2020-12-31
    Completion
    2022-01-31
    Enrolment
    120

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer Female; Pain, Postoperative
    InterventionBromelain/Boswellia Serrata Casperome; Centella Asiatica/Vitamins; Placebo
    PhasePhase 4
    Registry statusUnknown

  • Inhalation of Vapor With Medication (Diclofenac Sodium, Menthol, Methyl Salicylate and N-Acetyl Cysteine) Reduces Oxygen Need and Hospital Stay in COVID-19 Patients - A Case Control Study

    NCT04900129 · start 2020-12-01

    Registered record
    Registry ID
    NCT04900129
    Conditions
    Covid19
    Interventions
    Menthol 0.02%, Methyl salicylate 0.05%, N- Acetyl cysteine 1.2 gm%, and Diclofenac sodium 1gm%
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2020-12-01
    Completion
    2020-12-30
    Enrolment
    43

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCovid19
    InterventionMenthol 0.02%, Methyl salicylate 0.05%, N- Acetyl cysteine 1.2 gm%, and Diclofenac sodium 1gm%
    PhasePhase 1
    Registry statusCompleted